Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8996237 | 1.00 | MAPT (0.47) | MAPTHTTALDH1A1TDP1GAA | |
| SCHEMBL10004271 | 1.00 | MAPT (0.47) | MAPTHTTALDH1A1TDP1GAA | |
| SCHEMBL8996178 | 0.84 | PKM (0.57) | MAPTHTTALDH1A1LMNAKLK7 | |
| SCHEMBL8996151 | 0.84 | PKM (0.57) | MAPTHTTALDH1A1LMNAKLK7 | |
| SCHEMBL3263015 | 0.84 | HTT (0.47) | MAPTHTTALDH1A1TDP1GAA | |
| SCHEMBL8996243 | 0.84 | HTT (0.47) | MAPTHTTALDH1A1TDP1GAA | |
| SCHEMBL3263011 | 0.84 | HTT (0.47) | MAPTHTTALDH1A1TDP1GAA | |
| SCHEMBL3150674 | 0.84 | TDP1 (0.47) | MAPTALDH1A1TDP1GAALMNA | |
| SCHEMBL10003453 | 0.84 | LMNA (0.45) | HTTALDH1A1TDP1GAALMNA | |
| SCHEMBL3264266 | 0.84 | CA12 (0.44) | MAPTHTTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594843-B1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative | TAKASAGO PERFUMERY CO LTD (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7601842-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | AADAT, KMO, ALDH7A1 | MAPT 4178/4885HTT 2343/4885ALDH1A1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.